Health‐related quality of life measures in genetic disorders: An outcome variable for consideration in clinical trials
- 20 July 2009
- journal article
- research article
- Published by Wiley in American Journal Of Medical Genetics Part C-Seminars In Medical Genetics
- Vol. 151C (3), 255-260
- https://doi.org/10.1002/ajmg.c.30217
Abstract
The field of medical genetics is rapidly advancing, and therapeutic options to treat genetic syndromes are becoming increasingly available. An understanding of the pathophysiology of various genetic disorders has provided researchers the opportunity to propose and test pharmacologic agents in preclinical murine models with hopes of translation to human trials. The development of clinical trials can be costly and time consuming, particularly for rare conditions. Pilot feasibility studies should be performed when designing clinical trials for genetic disorders. The development and selection of appropriate outcome measures are particularly paramount in the implementation of clinical trials. The selection of inappropriate outcome measures can lead to non‐measurable differences or clinically insignificant findings. In addition, just as age appropriate measures are needed, some instruments may not apply to populations with specific genetic disorders that have significant cognitive and physical impairment, as the measures may not be sensitive enough to identify clinically significant changes. In the last decade, health‐related quality of life measures (HRQOL) have been increasingly included as an outcome measure in clinical trials. While traditional clinical outcomes are important, these newly developed instruments should be considered along with clinical indicators as measures of effect in clinical trials of interventions in genetic disorders.Keywords
This publication has 47 references indexed in Scilit:
- Health-Related Quality of Life in Children with Neurofibromatosis Type 1: Contribution of Demographic Factors, Disease-Related Factors, and BehaviorThe Journal of Pediatrics, 2008
- Effect of Simvastatin on Cognitive Functioning in Children With Neurofibromatosis Type 1JAMA, 2008
- Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndromeAmerican Heart Journal, 2007
- Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1The Journal of Pediatrics, 2006
- Discordance between physician's and parent's global assessments in juvenile idiopathic arthritisRheumatology, 2006
- Free Vascular Fibular Transfer in Congenital Pseudoarthrosis of the Tibia: Results of the EPOS Multicenter StudyJournal of Pediatric Orthopaedics B, 2000
- Treatment Approaches for Congenital Pseudarthrosis of Tibia: Results of the EPOS Multicenter StudyJournal of Pediatric Orthopaedics B, 2000
- Distal Metaphyseal Tibial NonunionPublished by Wolters Kluwer Health ,1990
- Congenital Pseudarthrosis of the TibiaClinical Orthopaedics and Related Research, 1982
- Surgical and Electrical Methods in the Treatment of Congenital and Posttraumatic Pseudarthrosis of the TibiaPublished by Wolters Kluwer Health ,1981